SRTS — Sensus Healthcare, Inc.

Sensus Healthcare Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $6.9 million, down from $8.8 million in Q3 2024.
• Units Sold: 16 systems in Q3 2025 compared to 27 in Q3 2024.
• Gross Profit: $2.7 million (39.1% gross margin) vs. $5.2 million (59.1% gross margin) in the prior year.
• Operating Expenses: Increased to $5.3 million from $3.7 million year-over-year.
• Net Loss: $0.9 million ($0.06 per share) compared to a net income of $1.2 million ($0.07 per share) in Q3 2024.
• Adjusted EBITDA: Negative $2.4 million vs. positive $1.6 million in the prior year.
• Cash Position: $24.5 million at quarter-end, up from $22 million at the end of 2024.

2. Strategic Updates and Business Highlights

• CPT Codes: CMS introduced new CPT codes for superficial radiotherapy (SRT), increasing reimbursement rates by over 300%, which is expected to enhance demand and adoption of SRT in dermatology.
• System Shipments: 16 SRT systems shipped in Q3, including 3 to China, bringing total global sales to over 900 systems.
• Utilization Trends: FDA treatment volumes increased by 20% from Q2, marking the third consecutive quarter of double-digit growth, with a 157% increase since the launch of the Fair Deal Agreement program.
• International Expansion: Continued interest in international markets, especially China, with plans for regulatory submissions in additional countries.

3. Forward Guidance and Outlook

• Q4 Expectations: Anticipation of strong demand due to the new reimbursement codes, with expectations to potentially reach breakeven or profitability in Q4.
• Future Sales: The company expects to sell approximately 1,000 SRT systems by 2026.
• International Revenue Growth: Aiming for international sales to represent about 20% of total revenue in the next 12-24 months, up from 5-10%.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The decrease in revenue and units sold compared to the previous year raises concerns about market penetration and customer acquisition.
• Increased Operating Expenses: Higher costs in R&D and marketing could pressure margins moving forward.
• Net Loss: The company reported a significant net loss, contrasting sharply with the previous year’s profitability.
• Regulatory Challenges: Ongoing uncertainties related to reimbursement codes and utilization of ultrasound in treatment could pose risks to future sales.

5. Notable Q&A Insights

• Utilization Trends: Management reported a 20% increase in utilization from Q2 and a 152% increase year-to-date, indicating strong patient demand for non-invasive treatments.
• Impact of CPT Codes: The new reimbursement codes are expected to enhance sales of the SRT-100, with management confident that they will not significantly impact the FDA program.
• Pent-Up Demand: There is a backlog of pending sites that are expected to go live in Q4, driven by increased clarity on reimbursement and strong market interest.
• International Sales Strategy: The company is optimistic about expanding its international footprint, particularly in Asia, and plans to submit for regulatory clearance for the Vision product in China.

This summary encapsulates the key points from Sensus Healthcare's Q3 2025 earnings call, highlighting both the positive developments and the challenges faced by the company.